From Services to Software: Labbit's Bold Bet on a New LIMS Era

VANCOUVER, BC – April 20, 2026 – In a decisive move that signals a full pivot from its origins, laboratory informatics company Labbit announced today it has officially retired the Semaphore Solutions brand. The consolidation completes a multi-year strategic transformation, shifting the company from a services-oriented firm implementing various laboratory systems to a dedicated software vendor focused entirely on its proprietary Labbit Laboratory Information Management System (LIMS) platform.

For over a decade, Semaphore Solutions built a reputation for designing and implementing complex LIMS solutions for regulated laboratories. Now, the company is betting its future on a single product born from that extensive experience, a move that reflects broader trends in a market grappling with increasingly complex scientific workflows and rigid legacy software.

A Strategic Metamorphosis

The brand consolidation is the final step in a strategic realignment that began over a year ago. The company, which once offered professional services across multiple LIMS platforms, has systematically transitioned its entire operation—from product development to service delivery—to support the Labbit platform exclusively. This positions Labbit as a specialized software provider for demanding fields such as molecular diagnostics, cell and gene therapy, pharmaceutical R&D, and manufacturing quality control.

The Labbit platform itself is the direct result of the Semaphore team's years in the trenches. They witnessed firsthand the limitations of existing systems, which often forced labs to adapt their scientific processes to the software's constraints, rather than the other way around.

"We spent years implementing the leading LIMS platforms on the market. We saw firsthand what worked and what didn't," said Peter Smith, CEO of Labbit, in today's announcement. "We built Labbit because we believed regulated labs deserved a system that adapts to how they actually work, not one that forces them to work around its limitations. Retiring the Semaphore name reflects what's been true for a while now: Labbit is our entire focus for both the services and product teams."

This evolution from a service provider to a product-centric company is significant. It allows for a singular focus on innovation, enabling the firm to channel its deep domain expertise into a single, cohesive solution designed to solve the industry's most pressing data management challenges.

Redefining Lab Workflows with Modern Tech

At the heart of Labbit's strategy is a technological architecture designed to offer flexibility and adaptability where legacy systems often provide rigidity. The platform is built on two key differentiators: visual BPMN (Business Process Model and Notation) workflow modeling and a knowledge graph database.

BPMN is a standardized graphical language that allows laboratory professionals to design, execute, and modify complex workflows visually, without writing a single line of code. This no-code approach democratizes workflow management, empowering the scientists and lab managers who understand the processes best to make changes themselves. It eliminates the long, costly development cycles typically required to update workflows in older LIMS, a critical advantage in fast-evolving fields like genomics and precision medicine. For customers like the personal genomics company Helix, this capability has been transformative, reducing workflow development timelines from years to mere days and enabling rapid pivots in testing capacity.

Underpinning this workflow flexibility is Labbit's knowledge graph database. Traditional LIMS often rely on rigid, table-based relational databases that require a predefined data model. This structure can become a significant bottleneck when scientific understanding evolves or new types of data need to be incorporated. In contrast, a knowledge graph focuses on entities and the intricate relationships between them, allowing the data model to evolve organically. This means labs are not locked into a brittle data structure and can capture complex sample genealogies—where one sample may yield dozens of derivatives—with far greater accuracy and context.

This modern data architecture also makes lab data inherently AI-ready. By capturing the deep, interconnected relationships between data points, the knowledge graph ensures that information is context-rich and structured for advanced analytics, predictive modeling, and machine learning applications. This aligns with the growing industry demand for systems that adhere to FAIR (Findable, Accessible, Interoperable, Reusable) data principles, preparing labs for the next wave of data-driven scientific discovery.

Navigating a Competitive and Complex Market

Labbit's focused approach enters a dynamic and competitive LIMS market, which is projected to reach $3.8 billion by 2029. The growth is fueled by the very challenges Labbit aims to solve: the explosive complexity of workflows in molecular diagnostics and cell and gene therapy (CGT), the demand for scalable cloud-based solutions, and the non-negotiable requirements for regulatory compliance.

Modern labs in these regulated spaces must adhere to a stringent alphabet soup of standards, including 21 CFR Part 11, SOC 2, HIPAA, CLIA, and GMP. These regulations demand meticulous audit trails, data integrity, and process traceability—all areas where manual processes and inflexible software fall short. Labbit's platform is designed with this in mind, offering 21 CFR Part 11 readiness, SOC 2 Type II certification, and HIPAA compliance out of the box.

By specializing in these high-complexity, high-regulation environments, Labbit is carving out a niche against larger, more established enterprise LIMS providers. While many legacy systems were built for a different era of lab science, Labbit's modern architecture is purpose-built for the intricate, multi-faceted data streams generated by today's NGS sequencers, automated liquid handlers, and complex biologic manufacturing processes.

Proven in the Field: From Theory to Practice

The company's strategy is already validated by its adoption in several high-throughput, high-complexity laboratories. Industry leaders like Helix, Veracyte, and BillionToOne are currently using the Labbit platform to manage critical workflows in clinical diagnostics and precision medicine.

The case of Helix is particularly illustrative. Before adopting Labbit, the company's large-scale clinical exome sequencing lab was hampered by a legacy LIMS that could not scale with fluctuating sample volumes or adapt to new workflow demands without significant IT intervention. The switch to Labbit's cloud-based platform provided the operational agility needed to not only manage its core business but also to rapidly scale COVID-19 testing. The result was dramatically faster sample processing times, reduced operational costs, and an empowered IT team freed from constant maintenance.

Feedback from other customers echoes this sentiment. Leaders at genomics firms have praised the platform's foresight in building flexible workflows that anticipate future needs, mitigating friction when shifting between research projects. The system is consistently recognized for its ability to unify lab operations, ensure compliance, and ultimately reduce time-to-market for new assays and therapies.

With the retirement of the Semaphore Solutions name, the company has drawn a clear line in the sand. It is no longer a general contractor for laboratory informatics but a focused architect of a specific vision for the lab of the future. This strategic consolidation under the Labbit brand is a declaration of confidence in its product and a commitment to providing regulated labs with the adaptable, data-centric tools needed to drive the next generation of scientific innovation.